Games for a new climate: experiencing the complexity of future risks

This repository item contains a single issue of the Pardee Center Task Force Reports, a publication series that began publishing in 2009 by the Boston University Frederick S. Pardee Center for the Study of the Longer-Range Future.This report is a product of the Pardee Center Task Force on Games for a New Climate, which met at Pardee House at Boston University in March 2012. The 12-member Task Force was convened on behalf of the Pardee Center by Visiting Research Fellow Pablo Suarez in collaboration with the Red Cross/Red Crescent Climate Centre to “explore the potential of participatory, game-based processes for accelerating learning, fostering dialogue, and promoting action through real-world decisions affecting the longer-range future, with an emphasis on humanitarian and development work, particularly involving climate risk management.” Compiled and edited by Janot Mendler de Suarez, Pablo Suarez and Carina Bachofen, the report includes contributions from all of the Task Force members and provides a detailed exploration of the current and potential ways in which games can be used to help a variety of stakeholders – including subsistence farmers, humanitarian workers, scientists, policymakers, and donors – to both understand and experience the difficulty and risks involved related to decision-making in a complex and uncertain future. The dozen Task Force experts who contributed to the report represent academic institutions, humanitarian organization, other non-governmental organizations, and game design firms with backgrounds ranging from climate modeling and anthropology to community-level disaster management and national and global policymaking as well as game design.Red Cross/Red Crescent Climate Centr

Augmented reality-based application design with rapid prototyping method to support practicum during the covid-19 pandemic

The COVID-19 pandemic that has occurred throughout the world has hampered the world of education in carrying out the learning process. It requires the world of education to make rapid changes to the concept of learning so that the results of the learning process remain following the curriculum. However, during a pandemic, students are forced to study from home. Of course, this limits the essence of the practicum, which has to be done in the laboratory because students need interaction activities with machines. Augmented reality (A.R.) is a technology that allows users to interact with virtual objects. In this study, the application design is carried out using the rapid prototyping method, which can quickly accommodate the application development process. This study proves that AR-based applications can increase the understanding of 58% of students about the use of lathe, milling and 3D printing machines

ResistanceSim: development and acceptability study of a serious game to improve understanding of insecticide resistance management in vector control programmes.

The use of insecticides is the cornerstone of effective malaria vector control. However, the last two decades has seen the ubiquitous use of insecticides, predominantly pyrethroids, causing widespread insecticide resistance and compromising the effectiveness of vector control. Considerable efforts to develop new active ingredients and interventions are underway. However, it is essential to deploy strategies to mitigate the impact of insecticide resistance now, both to maintain the efficacy of currently available tools as well as to ensure the sustainability of new tools as they come to market. Although the World Health Organization disseminated best practice guidelines for insecticide resistance management (IRM), Rollback Malaria's Vector Control Working Group identified the lack of practical knowledge of IRM as the primary gap in the translation of evidence into policy. ResistanceSim is a capacity strengthening tool designed to address this gap. The development process involved frequent stakeholder consultation, including two separate workshops. These workshops defined the learning objectives, target audience, and the role of mathematical models in the game. Software development phases were interspersed with frequent user testing, resulting in an iterative design process. User feedback was evaluated via questionnaires with Likert-scale and open-ended questions. The game was regularly evaluated by subject-area experts through meetings of an external advisory panel. Through these processes, a series of learning domains were identified and a set of specific learning objectives for each domain were defined to be communicated to vector control programme personnel. A simple "game model" was proposed that produces realistic outputs based on player strategy and also runs in real-time. Early testing sessions revealed numerous usability issues that prevented adequate player engagement. After extensive revisions, later testing sessions indicated that the tool would be a valuable addition to IRM training

Current Topics in Neglected Tropical Diseases

Neglected tropical diseases (NTDs) is a diverse group of communicable diseases that prevail in tropical and subtropical conditions in 149 countries. NTDs affect more than one billion people and cost developing economies billions of dollars every year. According to the World Health Organization (WHO), NTDs mainly affect populations living in poverty, without adequate sanitation, and in close contact with infectious vectors, domestic animals, and livestock. Migration, as well as climate change and variability, are key factors in NTD prevalence. Therefore, NTDs deserve more study. Recently, viruses transmitted by vectors (arboviruses) that affect not only people living in the tropics, but also travelers and migrating populations, have been causing epidemics. Examples of these viruses include Dengue, Chikungunya, Zika, Mayaro, and encephalitis viruses. These viruses emerge and reemerge in multiple regions of the world, as occurred in the Americas recently (2013-2017) with Chikungunya and Zika. This book aims to update the significant epidemiological and clinical research of NTDs in many aspects with a multinational perspective

Drug repurposing clinical trials in the search for life-saving COVID-19 therapies; research targets and methodological and ethical issues

Introduction: So far, there is no vaccine, nor are there effective drugs to treat COVID-19, an emerging viral respiratory infection deadlier than influenza. Objective: To take a snapshot picture of planned and ongoing clinical research addressing drugs potentially useful for treating SAR-CoV-2 infections. Method: A search was conducted (20 April 2020) in an international registry of clinical studies (https://ClinicalTrials.gov, US NIH). After excluding observational studies and other interventions that fell outside the scope of this study, 294 research protocols (out of 516 retrieved protocols) were selected for analysis. Results: Of 294 included trials, 249 were Randomized Controlled Trials (RCT), 118 of which were double-, triple- or quadruple-blinded studies. The interventions (drug therapies) were compared with “standard-of-care” (SOC) or with the placebo plus SOC, or yet with presumed “active” comparators. RCT focused on the primary treatment of the disease (inhibitors of viral replication) or on the therapy for resolution of hyperinflammation in pneumonia/Acute Respiratory Distress Syndrome (ARDS) and thromboembolism associated with SARS-CoV-2. The trials found in the database involve existing antiviral compounds and drugs with multiple modes of antiviral action. Antiparasitic drugs, which inhibited viral replication in cell-culture assays, are being tested as well. Regarding the adjunctive immunomodulatory, anti-inflammatory and antithrombotic therapies, a number of drugs with distinct pharmacological targets are under investigation in trials enrolling patients with severe COVID-19. Conclusions: Although many clinical studies of drugs for COVID-19 are planned or in progress, only a minority of them are sufficiently large, randomized and placebo-controlled trials with masking and concealment of allocation. Owing to methodological limitations, only a few clinical trials found in the registry are likely to yield robust evidence of effectiveness and safety of drugs repurposable for COVID-19.TÍTULO PT: Ensaios clínicos para reposicionamento de medicamentos para COVID-19 na busca de terapias para salvar vidas; alvos de pesquisa, e questões metodológicas e éticas Introdução: Até agora, não há vacinas ou medicamentos eficazes para tratar COVID-19, uma infecção viral respiratória emergente mais letal do que a gripe. Objetivo: Desenhar um quadro das pesquisas planejadas e em curso sobre medicamentos potencialmente úteis para tratar infecções por SARS-CoV-2. Método: Um levantamento foi realizado (20 de abril de 2020) em um registro internacional de estudos clínicos (https://ClinicalTrials.gov, US NIH). Após excluir estudos observacionais e outras interveções fora do escopo deste estudo, 294 protocolos (de 516 identificados na busca) foram selecionados para análise. Resultados: De 294 ensaios incluídos, 249 eram Ensaios Controlados Randomizados (ECR), dos quais 118 eram estudos duplo-, triplo- ou quadruplo-cego. As intervenções (medicamentos testados) foram comparadas com o “tratamento padrão” (TP) ou com placebo mais TP, ou ainda com comparadores supostamente ativos. ECR abordaram o tratamento primário da doença (inibidores da replicação viral) ou a resolução da super-inflamação na pneumonia e Síndrome do Desconforto Respiratório Agudo (SDRA), e do tromboembolismo associados ao SARS-CoV-2. Os ensaios localizados no registro envolviam fármacos antivirais com múltiplos modos de ação e medicamentos anti-parasitários que inibem a replicação viral em cultura de células. Em relação às terapias imunomodulatória, antiinflamatória e antitrombótica adjuvantes, inúmeros medicamentos com alvos farmacológicos distintos também estão sendo investigados em ensaios envolvendo pacientes graves com COVID-19. Conclusões: Embora muitos ensaios clínicos de medicamentos para COVID-19 tenham sido planejados e estejam em andamento, apenas uma minoria deles são estudos suficientemente grandes, randomizados, controlados com placebo e com mascaramento, e ocultação da alocação. Em virtude das limitações metodológicas apontadas, provavelmente apenas uns poucos ensaios clínicos fornecerão evidências robustas da eficácia e segurança de medicamentos potencialmente redirecionáveis para COVID-19

Mosquitopia

This edited volume brings together natural scientists, social scientists and humanists to assess if (or how) we may begin to coexist harmoniously with the mosquito. The mosquito is humanity’s deadliest animal, killing over a million people each year by transmitting malaria, yellow fever, Zika and several other diseases. Yet of the 3,500 species of mosquito on Earth, only a few dozen of them are really dangerous—so that the question arises as to whether humans and their mosquito foe can learn to live peacefully with one another. Chapters assess polarizing arguments for conserving and preserving mosquitoes, as well as for controlling and killing them, elaborating on possible consequences of both strategies. This book provides informed answers to the dual question: could we eliminate mosquitoes, and should we? Offering insights spanning the technical to the philosophical, this is the “go to” book for exploring humanity’s many relationships with the mosquito—which becomes a journey to finding better ways to inhabit the natural world. Mosquitopia will be of interest to anyone wanting to explore dependencies between human health and natural systems, while offering novel perspectives to health planners, medical experts, environmentalists and animal rights advocates